Clinical trial

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT00454818

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-03-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2007-03-01Date precision: month

Registry last updated2014-08-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Heart Failure, Congestiveunresolved

Dilated Cardiomyopathyunresolved

Interventions

MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)GENETIC

Placebo InfusionPROCEDURE

MYDICAR Phase 2 (Placebo-controlled, Randomized Study)GENETIC

Sponsors & collaborators

Celladon Corporationlead sponsor

Mapped research locations

New YorkNew York, United States2 ChicagoIllinois, United States2 ClevelandOhio, United States2 San DiegoCalifornia, United States2 HoustonTexas, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 St LouisMissouri, United States1 PittsburghPennsylvania, United States1 CincinnatiOhio, United States1 PortlandOregon, United States1 Winston-SalemNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00454818 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.